Nordea initiates coverage of probiotic company Biogaia with a Buy rating and a price target of SEK 140, corresponding to a P/E ratio of 29 for 2027.
The bank sees support for continued double-digit growth through increased pricing and new premium products. Nordea expects annual revenue growth of 13 percent during 2025–2030, clearly above consensus, and annual EBIT growth of 19 percent.
Risks include weaker consumer demand, increased competition following patent expirations and a weaker dollar.